Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma.

Cellular immunology - 1 Jun 1995

Dumont F J, Staruch M J, Grammer T, Blenis J, Kastner C A, Rupprecht K M

Abstract excerpt

Rapamycin (RAP) disrupts signaling events implicated in cytokine-dependent proliferation of lymphocytes and other cells. This action is known to involve the formation of molecular complexes between the drug and intracellular binding proteins, termed FKBPs. However, the biochemical target(s) for the effector RAP-FKBP complexes remain uncharacterized. As an approach to explore the mechanism of action of RAP, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carrier Proteins
Share to Cell Division
Share to DNA-Binding Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Flow Cytometry

Share to Mutation

Share to RNA, Messenger

Source

Identifiers

PMID: 7538911
DOI: 10.1006/cimm.1995.1100

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma.PMID 7538911Read ↗

Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1.Semantic proximity Read ↗

Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.Semantic proximity Read ↗

Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.Semantic proximity Read ↗

The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain.Semantic proximity Read ↗

TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.Semantic proximity Read ↗

Rapamycin resistance in ataxia-telangiectasia.Semantic proximity Read ↗

The rapamycin sensitivity of human T-cell leukaemia virus type I-induced T-cell proliferation is mediated independently of the polypyrimidine motifs in the 5' long terminal repeat.Semantic proximity Read ↗

Missense mutations at the FKBP12-rapamycin-binding site of TOR1.Semantic proximity Read ↗

Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype.Semantic proximity Read ↗

The tyrosine89 residue of yeast FKBP12 is required for rapamycin binding.Semantic proximity Read ↗

Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.